Skip to content

Use of the Medical Device DECAP CO2 for the Treatment of Hypercapnic Respiratory Distress in Patients Under Noninvasive Ventilation

Use of the Medical Device DECAP CO2 for the Treatment of Hypercapnic Respiratory Distress in Patients Under Noninvasive Ventilation

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01774422
Acronym
DECAP CO2
Enrollment
32
Registered
2013-01-24
Start date
2013-01-31
Completion date
2015-01-31
Last updated
2013-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercapnia, Respiratory Distress Syndrome

Keywords

Hypercapnia, Respiratory Distress Syndrome, Extracorporeal CO2 remover, Noninvasive ventilation

Brief summary

The patients affected by severe chronic respiratory failure can develop hypercapnic decompensation leading to coma and death in a few hours. At present, the main treatment is noninvasive or invasive ventilation. The noninvasive invasive ventilation requires a minimum of consciousness to insure spontaneous ventilation. In case of noninvasive ventilation impossibility, invasive mechanical ventilation is proposed to patients, which is an aggressive therapy. Regularly, the patients undergo this aggressive therapy without having expressed their opinion. Indeed, a great majority of these patients with severe respiratory insufficiency did not anticipate directives in case of respiratory decompensation (acceptation of aggressive treatments). Efficiency of these aggressive therapies is still uncertain but certainly alters quality of life (discomfort, loss of autonomy…). After complete, clear, loyal and adapted information, a majority of patient do not wish to go on these aggressive therapies. At the time of the decompensation, the patients are incapable to express an opinion because of the hypercapnic narcosis. An extracorporeal CO2 remover device, such as the DECAP CO2, would quickly decrease the hypercapnia what would allow the patient to improve his state of consciousness and so to find the conditions of spontaneous ventilation required for the noninvasive ventilation. The DECAP CO2 device can be used to stop quickly the hypercapnic narcosis and to collect the wills of the patient on the choice of possible aggressive therapies. It is in this last condition that we wish to estimate the DECAP CO2 device.

Detailed description

After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study: * Noninvasive ventilation alone * Noninvasive ventilation associated with the DECAP CO2 device

Interventions

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

Adult patient suffering from severe chronic respiratory failure * Chronic obstructive pulmonary disease : stage III * Hypercapnic respiratory decomposition * No anticipated directive with the treating physician, pulmonologist or his family. * Challenged for invasive ventilation by critical care doctor, emergency doctor or pulmonologist ; due to the respiratory pathology severity or other (age, comorbidity) * Not challenged for a noninvasive ventilation * Failure of the noninvasive ventilation in intensive care unit (pH decrease due to hypercapnia after 2 hours of noninvasive ventilation Obtaining of the consent of the patient or the reliable person or the close relation

Exclusion criteria

* \- Patients who made anticipated directives (decision of the patient to have no tracheotomy, intubation, noninvasive ventilation) * Contraindication to heparin (active bleeding, Heparin-induced thrombocytopenia) * Patients \< 18 years and \> 90 years * Patients already included in another therapeutic trial * Pregnant woman or breast feeding * Legal incapacity

Design outcomes

Primary

MeasureTime frame
HypercapniaH24

Secondary

MeasureTime frame
Duration of judgment disabilityH72
Duration of blood pH normalizationH72
Duration of hypercapniaH72
GlasgowH0
SAPSII scores(Simplified Acute Physiology Score II)H24
Duration of noninvasive ventilationH72
Blood gasesH0
MortalityH72
MMSE (Mini Mental State Examination)H0
ACE ( Aid To Capacity Evaluation)scoresH0
SOFA scores(Sepsis-related Organ )H24
Blood GasesH24
Duration of hospitalizationH72

Contacts

Primary ContactPatrick LACARIN
placarin@chu-clermontferrand.fr04 73 75 11 95

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026